Akebia Therapeutics Inc

Despite the long-term downtrend, AKBA’s early Stage 1 base and the Bullish Pivot Point suggest upward mean-reversion potential. Price is currently extended above the rising short EMAs and testing resistance at the 50-day SMA without clear exhaustion, so execution should be deferred. We will await a pullback into the 9/21 EMA support zone near the base lows before initiating participation.

• ↑Vafcio net product revenue rose 60% YoY to $21.3M in Q2 2026
• ↑Patient enrollment grew 41% QoQ to over 10,500 active users
• ↓Total revenues fell 21% YoY to $49.1M, driven by Arixia declines